Joseph Stilwill, MD
A number of the findings in melanoma presented at the 2018 ASCO Annual Meeting were in the adjuvant setting, reporting benefits with BRAF/MEK inhibition as well as anti–PD-1 therapies, said Joseph Stilwill, MD, a medical oncologist at the Sarah Cannon Research Institute.
State of the Science Summit™, A Summer of Progress: Updates from ASCO 2018, Stilwill addressed recent advances in melanoma and the focus of research moving forward.
OncLive: What did you focus on in your presentation on melanoma?
: The really exciting advances in melanoma over the last year [have been in the] adjuvant [setting], both in the BRAF
-positive population as well as in the general population. BRAF and MEK inhibition, as well as anti–PD-1 therapy, have shown a significant benefit in the adjuvant setting and are less toxic than [previously approved] adjuvant therapy.
... to read the full story